title: Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.
abstract: Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo-controlled trials are needed to more fully evaluate the utility of famotidine in the treatment of schizophrenia.
authors.affiliation: Psychiatry Service, Department of Veterans Affairs Medical Center, Washington, D.C. 20422, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Rosse
authors.forename: K
authors.initials: K
authors.lastname: Kendrick
authors.forename: L C
authors.initials: LC
authors.lastname: Tsui
authors.forename: M
authors.initials: M
authors.lastname: Fay-McCarthy
authors.forename: J P
authors.initials: JP
authors.lastname: Collins
authors.forename: P
authors.initials: P
authors.lastname: Rosenberg
authors.forename: R J
authors.initials: RJ
authors.lastname: Wyatt
authors.forename: S I
authors.initials: SI
authors.lastname: Deutsch
mesh_terms: D015738:Famotidine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008972:Molindone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D015738:Famotidine; D008972:Molindone